Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma

NCT04069273 is registered in ClinicalTrials.gov with Harry H Yoon as lead sponsor.

NCT NCT04069273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04069273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma
Lead sponsor
Harry H Yoon
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 1, 2020
Completion date
December 10, 2027
Enrollment
58 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, gastric cancer, gastroesophageal cancer